Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization phase - Jan 2023 to December 2025
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(267)
•••
Comment by LaserStock29on May 04, 2022 5:36pm
201 Views
Post# 34656704

RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025

RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025
Patents on molecules means we hold a 6 shooter...... fire off one to a pharma and you have 5 independent bullets remaining.

If the Pharma wants all 6 bullets...... they have to pay big.. very big.  

That's why all the work done in 2017-2019  on 5-6 different indications were done


I hope Dr.Mandel has found time from 2019 AGM saying Toxicity studies need to be done to finally do it..   lord knows 3 years is enough time to run a couple months Tox study.









Rumpl3StiltSkin wrote: I don't mind If They JV or sell/license 1433 for NMIBC and then hold onto Rutherrin for all of the Solid tumor indications that will follow. I think that would work great. I would call that deal mostly independent. True independense is getting a big grant/order for the Covid vax/treatment from Public Health Canada so they don't have to JV on NMIBC.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities